{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:15:00Z","timestamp":1783134900725,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacig.2026.100731","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T23:46:43Z","timestamp":1779493603000},"page":"100731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologic readiness: Improving tuberculosis screening in an adult allergy and immunology clinic"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-6761","authenticated-orcid":false,"given":"Kimberly Lovie","family":"Murdaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Flen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaela Martina C.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyara C.","family":"Ramdhanie Lalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Lee-Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2026.100731_bib1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100731_bib2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2026.100731_bib3","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10209","key":"10.1016\/j.jacig.2026.100731_bib4","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacig.2026.100731_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8909834","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non\u2013anti-TNF\u2013targeted biologics","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jacig.2026.100731_bib6","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.4049\/jimmunol.1103298","article-title":"Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability","volume":"188","author":"Fallahi-Sichani","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jacig.2026.100731_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CM9.0000000000001948","article-title":"Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials","volume":"135","author":"Ji","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jacig.2026.100731_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","article-title":"Risk of tuberculosis infection in anti\u2013TNF-\u03b1 biological therapy: from bench to bedside","volume":"47","author":"Xie","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jacig.2026.100731_bib9","article-title":"Tuberculosis screening for patients on biologic medications: a single-center experience and society guideline review, Monroe County, New York, 2018-2021","volume":"36","author":"Maeda","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.jacig.2026.100731_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jbspin.2019.07.011","article-title":"Infectious adverse events in children with juvenile idiopathic arthritis treated with biological agents in a real-life setting: data from the JIRcohorte","volume":"87","author":"Dumaine","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jacig.2026.100731_bib11","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha\u2013neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.jacig.2026.100731_bib12","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jacig.2026.100731_bib13","article-title":"Indeterminate results of interferon gamma release assays in the screening of latent tuberculosis infection: a systematic review and meta-analysis","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacig.2026.100731_bib14","article-title":"A FOCUS-PDCA quality improvement model for reducing the distribution defect rate of sterile packages","volume":"13","author":"Huang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacig.2026.100731_bib17","series-title":"Bureau of Tuberculosis Control. Clinical policies and program manual","year":"2025"},{"issue":"9387","key":"10.1016\/j.jacig.2026.100731_bib18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(03)14333-4","volume":"362","author":"Frieden","year":"2003","journal-title":"Tuberculosis. Lancet"},{"key":"10.1016\/j.jacig.2026.100731_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"RR-15","key":"10.1016\/j.jacig.2026.100731_bib20","first-page":"1","article-title":"Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC","volume":"54","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jacig.2026.100731_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1183\/09031936.00070812","article-title":"Contact investigation for tuberculosis: a systematic review and meta-analysis","volume":"41","author":"Fox","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2026.100731_bib22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3201\/eid1703.100947","article-title":"Tuberculosis among health care workers","volume":"17","author":"Baussano","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jacig.2026.100731_bib23","first-page":"479","article-title":"Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large US claims database","volume":"25","author":"Feldman","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacig.2026.100731_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jurban\/78.3.550","article-title":"Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program","volume":"78","author":"Perlman","year":"2001","journal-title":"J Urban Health"},{"key":"10.1016\/j.jacig.2026.100731_bib25","first-page":"510","article-title":"The effectiveness and value of biologic therapies for the treatment of uncontrolled asthma","volume":"25","author":"Tice","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacig.2026.100731_bib26","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/art.39079","article-title":"Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D","volume":"67","author":"Yazdany","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacig.2026.100731_bib27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/14737167.2022.2117690","article-title":"The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States","volume":"22","author":"Ding","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jacig.2026.100731_bib28","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1001\/jamainternmed.2017.3941","article-title":"Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States with and without medical comorbidities in a simulation model","volume":"177","author":"Tasillo","year":"2017","journal-title":"JAMA Intern Med"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829326000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829326000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:14:56Z","timestamp":1783131296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829326000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2772829326000937"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100731","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic readiness: Improving tuberculosis screening in an adult allergy and immunology clinic","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100731"}}